Cell-Easy Becomes the First Private Pharmaceutical Company in France Allowed to Manufacture Stem Cells
9.6.2020 17:40:00 EEST | Business Wire | Press release
Cell-Easy, a start-up based in Toulouse specialized in stem cell therapy, announces today the signature of an agreement with the University Hospital Centre in Toulouse, as well as securing the authorization to open a pharmaceutical manufacturing plant dedicated to the production of stem cells - a first in France. This follows the announcement made last December of raising 1M€ capital investment.
Thanks to its innovative mass scale stem cells manufacturing process, Cell Easy aims to develop regenerative medicine through therapeutic solutions based on Advanced Therapy Medicinal Products compatible with affordable access for millions of patients.
The start-up has now signed a first partnership with the University Hospital Center in Toulouse and will be producing Mesenchymal stem cells (or stromal cells) sourced from qualified fat tissue in accordance with good manufacturing practices. A first clinical trial is on its way to fight against Alzheimer disease.
« Our ambition is to industrialize our proprietary stem cell manufacturing process to make Cell Therapy accessible to the largest number possible of patients. The aim is to cut costs by ten and increase production capacity beyond 100 0000 doses /year. » explains Pierre Monsan, DG of Cell-Easy and Founder of Toulouse White Biotechnology (TWB).
« Today, stem cell-based treatments represent a major therapeutic hope. What has been set up here is very much the expression of the way the University Hospital Centre approaches the development of innovative technologies, therapies and organizations that support new therapies founded on cross fertilization of talent and expertise. » says Marc Penaud, Executive Manager of the University Hospital Center in Toulouse.
Furthermore, the French Medicines Agency, also gave Cell-Easy the authorization to open a pharmaceutical plant to manufacture stem cell batches at large scale, in accordance with GMP (Good Manufacturing Practices) standards. This authorization makes Cell-Easy the only private pharmaceutical organization able to manufacture stem cells in France on an industrial scale. This firmly puts Cell-Easy on the European stage.
Capital investment is being secured to finance the quick implementation of their strategy in France but also in Europe where patients’ needs are high.
Cell-Easy will now be able to manufacture stem cells batches for industrial partners and is one of the world’s precursors in cell therapy.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200609005563/en/
Contact information
Press : Aurelie Mauries aurelie@oxygen-rp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Charted Launches ERP-Native E-invoicing Across EMEA1.9.2026 15:30:00 EEST | Press release
Charted, a leading accounts payable automation software and ERP services provider, today announced the expansion of Charted E-invoicing to support multiple countries spanning Europe, including Germany, France, Norway, Sweden, the Netherlands, Denmark and Finland. Further expansion to Italy, Romania, and Poland, will take place by the end of the quarter. These countries follow the official launch of Charted E-invoicing in Belgium, in May 2026. This expansion is designed to cement Charted support for users across EMEA, ensuring companies based in the region transacting on the PEPPOL network can remain compliant while keeping their accounts payable processes embedded inside their ERP. Charted E-invoicing works as a capability within Charted Invoice AI, to receive electronic invoices directly into the AP inbox, keeping the user experience identical no matter what type of invoice is being reviewed. This also consolidates invoice sources, both PDF and electronic, into one unified inbox. The
Riskified Expands its Risk Intelligence Platform with ARIA1.9.2026 15:00:00 EEST | Press release
Riskified (NYSE: RSKD), a global leader in ecommerce fraud detection and risk intelligence, today expanded its risk intelligence platform with ARIA (AI Risk Intelligence Analyst), a conversational AI capability built directly into the Riskified Control Center. Fraud teams today have access to vast amounts of data, but solving urgent business questions often still requires exporting files, building reports, or waiting for additional analysis. ARIA changes that by letting merchants ask questions in natural language and get answers in seconds, complete with charts and tables that support the analysis. With direct access to Riskified metrics and their own business-specific reporting logic, ARIA can investigate and quickly answer a wide range of questions within an existing workflow, including exploring performance trends, analyzing shifts across regions or payment methods, and uncovering patterns in order data. “ARIA is a powerful resource for executive-level communications, providing rapi
Perma-Pipe and Welspun Announce Memorandum of Understanding to Establish Pipe Manufacturing and Coating Facilities in Jordan1.9.2026 15:00:00 EEST | Press release
Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH) (“Perma-Pipe” or the “Company”), a global leader in engineered pipe solutions specialising in anti-corrosion coatings, insulation solutions, containment systems, custom fabrication and leak detection, today announced that it has signed, together with Welspun Corp Limited (“Welspun”), a Memorandum of Understanding (“MOU”) with the developers of Jordan’s National Water Carrier Project and the Government of the Hashemite Kingdom of Jordan to advance the development of pipe manufacturing and advanced coating facilities in Jordan. The parties intend to establish a joint venture to support the development and operation of these facilities. Transaction Description Under the terms of the MOU, Perma-Pipe and Welspun have partnered to establish an integrated pipe manufacturing and coating platform in Jordan capable of serving major water, oil and gas, energy, and infrastructure projects in the Kingdom and across surrounding regional markets.
Vasion ® Unlocks Windows PCs on Snapdragon Adoption with Native, Driverless Printing1.9.2026 15:00:00 EEST | Press release
Vasion is removing a critical barrier to modern Windows device adoption with native, driverless printing for PCs powered by Snapdragon® compute processors. The Vasion Spring 2026 release delivers a seamless, cloud-native print experience, eliminating the need for printer drivers, emulation, or parallel print environments. The collaboration with Qualcomm Technologies combines the PC ecosystem reach of Snapdragon with Vasion's print automation expertise. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260901581087/en/ Vasion fully supports Windows devices powered by Snapdragon with full Internet Printing Protocol (IPP) driverless printing support, enabling IT teams to modernize device fleets without disrupting operations or rearchitecting existing environments. Vasion fully supports Windows devices powered by Snapdragon with full Internet Printing Protocol (IPP) driverless printing support, enabling IT teams to modernize device
Compass Pathways to Participate in 2026 Cantor Global Healthcare Conference on September 9, 20261.9.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the 2026 Cantor Global Healthcare Conference on September 9, 2026 and will participate in a fireside chat at 3:20pm ET and a panel entitled “PSYCH! Accessing The New Wave of Psychedelics” at 4:30pm ET. A live audio webcast of the fireside chat will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation for treatment-resis
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom